• GlaxoSmithKline plc, of London, and the Biomedical Advanced Research and Development Authority (BARDA) agreed to a collaboration that will support the development of several antibiotics to fight antibiotic resistance and bioterrorism. The public-private agreement calls for the Department of Health and Human Services to provide $40 million for the initial 18-month agreement and up to $200 million if the agreement is renewed over five years. The agreement will be governed by a BARDA-GSK joint oversight committee that will monitor progress, make decisions on the allocation of funds and decide on the addition or removal of drug candidates from the portfolio.